Diffuse Cerebral Vasoconstriction (Call-Fleming Syndrome) and Stroke Associated with Antidepressants
Neurol 67:159-160, Noskin,O.,et al, 2006
Pesticide Exposure and Risk for Parkinsons Disease
Ann Neurol 60:197-203, Ascherio,A.,et al, 2006
Progressive Multifocal Leukoencephalopathy Revisited: Has the Disease Outgrown Its Name?
Ann Neurol 60:162-173, Koralnik,I.J., 2006
Recurrent Ibuprofen-Induced Aseptic Meningitis: Evidence Against an Antigen-Specific Immune Response
Neurol 67:539-540, Periard,D.,et al, 2006
Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006
Immune Reconstitution Inflammatory Syndrome in the CNS of HIV Infected Patients
Neurol 67:383-388, Venkataramana,A.,et al, 2006
Characteristics and Antecedents of Progressive Multifocal Leukoencephalopathy in an Insured Population
Neurol 67:884-886, Eng,P.M.,et al, 2006
Intra-Arterial Thrombolysis Is the Treatment of Choice for Basilar Thrombosis: Pro
Stroke 37:2436-2437,2440, Schellinger,P.D. &Hacke,W., 2006
Intra-Arterial Thrombolysis Is the Treatment of Choice for Basilar Thrombosis: Con
Stroke 37:2438-2439,2440, Ford,G.A., 2006
Tandem Internal Carotid Artery/Middle Cerebral Artery Occlusion: An Independent Predictor of Poor Outcome After Systemic Thrombolysis
Stroke 37:2301-2305, Rubiera,M.,et al, 2006
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
High-Dose Atorvastatin After Stroke or Transient Ischemic Attack
NEJM 355:549-559,613, The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, 2006
Using the Baseline CT Scan to Select Acute Stroke Patients for IV-IA Therapy
AJNR 27:1612-1616, Hill,M.E.,et al, 2006
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Poststroke C-Reactive Protein Is a Powerful Prognostic Tool Among Candidates for Thrombolysis
Stroke 37:1205-1210, Montaner,J.,et al, 2006
Good Outcomes in Ischemic Stroke Patients treated With Intravenous Thrombolysis Despite Regressing Neurological Symptoms
Stroke 37:1332-1333, Baumann,C.R.,et al, 2006
Mycophenolate Mofetil in Dermatomyositis: Is It Safe?
Neurol 66:1245-1247, Rowin,J.,et al, 2006
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Antiplatelets, ACE Inhibitors, and Statins Combination Reduces Stroke Severity and Tissue At Risk
Neurol 66:1153-1158, Kumar,S.,et al, 2006
Is IV Tissue Plasminogen Activator Beneficial in Patients With Hyperdense Artery Sign?
Neurol 66:1171-1174, Qureshi,A.I.,et al, 2006
MATILDE Regimen Followed by Radiotherapy is an Active Strategy Against Primary CNS Lymphomas
Neurol 66:1435-1438, Ferreri,A.J.M.,et al, 2006
Reasons Why Few Patients With Acute Stroke Receive Tissue Plasminogen Activator
Arch Neurol 63:661-664, Bambauer,K.Z.,et al, 2006
Transmission of Lymphocytic Choriomeningitis Virus by Organ Transplantation
NEJM 354:2235-2249, Fischer,S.A.,et al, 2006
Clinicopath Conf, Acute Ischemic Stroke
NEJM 354:2263-2271, Case 16:2006, 2006
Thrombolysis in Patients Older Than 80 Years With Acute Ischaemic Stroke: Canadian Alteplase for Stroke Effectiveness Study
JNNP 77:826-829,812, Sylaja, P.N.,et al, 2006
Safety of Mechanical Thrombectomy and Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke: Results of the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) Trial, Part I
AJNR 27:1177-1182, W.S. Smith, for the Multi MERCI Investigators, 2006
Ischemic Strokes After Cardiac Catheterization
Arch Neurol 63:817-821, Khatri,P. &Kasner,S.E., 2006
Comparison of Tissue Plasminogen Activator Administration Management Between Telestroke Network Hospitals and Academic Stroke Centers
Stroke 37:1822-1827, Audebert,H.,et al, 2006
Thrombolysis (Tissue Plasminogen Activator) in Stroke: A Medicolegal Quagmire
Stroke 37:1917-1922, Weintraub,M.I., 2006
Door to Thrombolysis: ER Reorganization and Reduced Delays to Acute Stroke Treatment
Neurol 67:334-336, Lindsberg,P.J.,et al, 2006
Intravenous Recombinant Tissue Plasminogen Activator in a Pregnant Woman With Cardioembolic Stroke
Stroke 37:2168-2169, Wiese,K.M.,et al, 2006
Ocular Myasthenia: Diagnosis, Treatment and Pathogenesis
The Neurologist 12:231-239, Kusner,L.,et al, 2006
Leukoaraiosis Is a Risk Factor for Symptomatic Intracerebral Hemorrhage After Thrombolysis for Acute Stroke
Stroke 37:2463-2466, Neumann-Haefelin,T.,et al, 2006
Discontinuation of Statin Treatment in Stroke Patients
Stroke 37:2640-2643, Endres,M. &Laufs,U., 2006
Leukoencephalopathy Induced by Levamisole Alone for the Treatment of Recurrent Aphthous Ulcers
Neurol 67:1065-1067, Liu,J.M.,et al, 2006
An Expedited Code Stroke Protocol Is Feasible and Safe
Stroke 37:2935-2939,2863, Sattin,J.A.,et al, 2006
The Stroke-Thrombolytic Predictive Instrument: A Predictive Instrument for Intravenous Thrombolysis in Acute Ischemic Stroke
Stroke 37:2957-2962,2865, Kent,D.M.,et al, 2006
Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?
Stroke 37:2963-2969, Kent,D.M.,et al, 2006
Long-Term Effect of Intra-Arterial Thrombolysis in Stroke
Stroke 37:3002-3007, Nedeltchev,K.,et al, 2006
Is Penumbral Imaging Useful for Extending the Treatment Window for Intravenous Tissue Plasminogen Activator?
Ann Neurol 60:499-501, Fisher,M., 2006
Prediction of Thrombolytic Efficacy in Acute Ischemic Stroke Using Thin-Section Noncontrast CT
Neurol 67:1846-1848, Kim,E.Y.,et al, 2006
Outcome of Acute Vertebrobasilar Occlusions Treated with Intra-Arterial Fibrinolysis in 180 Patients
AJNR 27:2042-2047, Schulte-Altedorneburg,G.,et al, 2006
Posterior Reversible Encephalopathy Syndrome in Infection, Sepsis, and Shock
AJNR 27:2179-2190, Bartynski,W.S.,et al, 2006
Immune Reconstitution Inflammatory Syndrome Associated with PML in AIDS: A Treatable Disorder
Neurol 67:1692-1694, Martinez,J.V.,et al, 2006
Predicting Abnormal Coagulation in Ischemic Stroke: Reducing Delay in rt-PA Use
Neurol 67:1665-1667, Gottesman,R.F.,et al, 2006
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Arch Neurol 63:1388-1393, Gladstone,D.E.,et al, 2006
Treatment With Interferon beta-1b Delays Conversion to Clinically Definite and McDonald MS in Patients With Clinically Isolated Syndromes
Neurol 67:1242-1249, Kappos,L.,et al, 2006
Infusion-Related Hypersensitivity Reactions During Natalizumab Treatment
Neurol 67:1717-1718, Phillips,J.T.,et al, 2006
Glioma Therapy in Adults
The Neurologist 12:279-292, Norden,A.D. &Wen,P.Y., 2006